Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 3Q Financial Reports | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

3Q Financial Reports

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck & Co.

3Q Revenues: $5.4 billion (flat)

3Q Earnings: $940.6 (-34%)

YTD Revenues: $16.6 billion (+2%)

YTD Earnings: $4 billion (+13%)

Comments: Worldwide sales for Singulair were $868 million for the quarter, up 25%. Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, exceeded $1 billion for the quarter. Vaccine sales were $555 million, up 64% as a result of the launch of Rotateq, Zostavax and Gardasil, and the strong performance of Proquad. Restructuring costs were $49.6 million for the quarter. The company reserved an additional $598 million in the quarter for future Vioxx legal defense costs.

Schering-Plough

3Q Revenues: $2.6 billion (+13%)

3Q Earnings: $309 million (earnings were $65 million 3Q2005)*

YTD Revenues: $7.9 billion (+11%)

YTD Earnings: $940 million (earnings were $143 million YTD2005)

Comments: Sales increase for the quarter was driven by growth in prescription pharmaceuticals, including higher sales of Remicade, Nasonex and Temodar. Remicade sales were up 34% to $317 million. Nasonex sales were up 30% to $221 million. Temodar sales were up 18% to $179 million. Global cholesterol joint venture sales, which include Vytorin and Zetia, reached more than $1 billion in the quarter.

*3Q2005 results included a charge of $124 million related to an R&D payment for exercising rights to develop and commercialize golimumab.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters